LUMINARE is a startup in the analytics industry with a mission to address sepsis, the #2 killer in hospitals, making their slogan, "MAKE SEPSIS THE #2 KILLER IN HOSPITALS" quite impactful. Founded in 2017 and headquartered in the United States, the company has shown strong potential. Their recent milestone includes a significant $3.40M Seed Round investment received on 01 November 2022.
Their innovative approach sets them apart as they don't just assist underperforming hospitals in achieving a passing grade in sepsis outcomes. They have managed to partner with industry leaders like Cedars-Sinai Hospital (#1 in California, #2 in the US) to drive even better standards of care. This demonstrates a strategic positioning within the healthcare sector and the ability to work with top-tier establishments.
LUMINARE's unique value proposition also lies in their ability to enhance the performance of already high-performing hospitals, setting them apart from the competition. Their capability to elevate the standards of care in leading medical facilities further strengthens their position in the market.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Seed Round | $3.40M | - | 01 Nov 2022 | |
Seed Round | $2.00M | - | 26 Aug 2020 | |
Venture Round | $1.15M | - | 07 Oct 2019 | |
Pre Seed Round | $497.49K | - | 14 Jun 2017 |
No recent news or press coverage available for Luminare.